Modifi Biosciences, Inc., a developer of direct DNA modification enabled cancer therapeutics, has been acquired by Merck for $30 million upfront. Modifi Biosciences shareholders are also eligible to receive potential milestone payments totaling up to $1.3 billion.   Modifi Biosciences has developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase (MGMT). Modifi Biosciences’ research and subsequen...